X4 PHARMACEUTICALS, INC Total Liabilities and Equity
X4 PHARMACEUTICALS, INC (XFOR) had Total Liabilities and Equity of $253.06 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-06
- 2026-06-30: Liabilities and Equity $253.06M.
- 2026-03-31: Liabilities and Equity $270.28M.
- 2025-12-31: Liabilities and Equity $290.46M.
- 2025-09-30: Liabilities and Equity $163.56M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $253.06M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $270.28M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $290.46M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $163.56M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $105.17M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $130.01M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $146.45M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $178.16M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $210.61M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $112.18M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $147.26M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $173.29M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $173.40M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $124.41M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $155.59M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $113.41M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $81.02M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $99.63M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $117.18M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $120.52M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $141.66M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $161.03M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $122.87M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $133.13M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $142.53M 10-Q · filed 2020-08-04 | |
| 2020-03-31 | $153.72M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $160.70M 10-K · filed 2021-03-19 | |
| 2019-09-30 | $109.54M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $133.51M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $62.55M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $9.94M 10-K · filed 2020-03-12 | $36.00M 10-K · filed 2019-03-11 |
| 2018-09-30 | $45.90M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $57.21M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $69.22M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $81.25M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |